PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
17-Feb-2025 Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 Formycon AG
14-Feb-2025 Nxera Pharma Proposes Changes to its Board of Directors Nxera Pharma
14-Feb-2025 Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 Nxera Pharma
14-Feb-2025 Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Sanofi
13-Feb-2025 First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 Pentixapharm Holding AG
13-Feb-2025 Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Sanofi
13-Feb-2025 Cytovation Appoints Martin Dewhurst to its Board of Directors Cytovation
13-Feb-2025 Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany Santhera Pharmaceuticals
13-Feb-2025 Thermo Fisher Scientific’s New Spatial Imaging System Enables Researchers to Generate High-quality Data, Making it Easier to Enter the Field of Spatial Tissue Proteomics Thermo Fisher Scientific
13-Feb-2025 EVERSANA Named a Vault Top Consulting Firm for Fourth Consecutive Year in North America, Third Year in Asia Pacific Region EVERSANA
13-Feb-2025 Genmab Publishes 2024 Annual Report Genmab
13-Feb-2025 Eckert & Ziegler Affected by Cyber Attack  Eckert & Ziegler SE
13-Feb-2025 Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative BRAIN Biotech AG
13-Feb-2025 DOUGLAS Group starts with solid growth into financial year 2024/25 Douglas AG
13-Feb-2025 SCHOTT Pharma records good start into fiscal year and confirms full year outlook SCHOTT Pharma AG & Co. KGaA
12-Feb-2025 Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform Seaport Therapeutics
12-Feb-2025 OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod OKYO Pharma
12-Feb-2025 Trading Update for the year ended 31 December 2024 AOTI, INC.
12-Feb-2025 BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) UCB
12-Feb-2025 Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA Lundbeck